Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

Background. Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy. We explored its effectiveness in patients with leukemia receiving cytarabine-based chemotherapy. Methods. Patients were randomized to ondansetron (OND) 8 mg IV 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Badar, Talha, Cortes, Jorge, Borthakur, Gautam, O'Brien, Susan, Wierda, William, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Kadia, Tapan, Poku, Rebeca, Kantarjian, Hagop, Mattiuzzi, Gloria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310492/
https://www.ncbi.nlm.nih.gov/pubmed/25654108
http://dx.doi.org/10.1155/2015/497597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310492/
https://www.ncbi.nlm.nih.gov/pubmed/25654108
http://dx.doi.org/10.1155/2015/497597

Ejemplares similares